Clinicians' Corner in Dyslipidemia

Multiple Challenges With Statin Selection

Statin-Associated Muscle Symptoms vs Statin Intolerance

GAUSS 3 Study Design

GAUSS 3 Study Implications

Nonstatin Therapy for Adjunct LDL-Lowering

PCSK9 Inhibitors Dosing and Administration

PCSK9 Inhibitors Indications

FOURIER Trial Design

Summary of Effects of PCSK9I Evolocumab

FOURIER Trial: Relationship Between Achieved LDL-c Levels at One Month to Measures of Benefit

FOURIER Safety

Nonstatin Recommendations From Treatment Guidelines

Guideline Recommendations for Additional LDL-C Reduction With Nonstatin Therapy

When to Consider Nonstatin Therapy

Alirocumab ODYSSEY Outcomes Trial

Alirocumab ODYSSEY Outcomes Trial Results

Navigating the Prior Authorization Process Clinical Pearls

Statin-Associated Myopathy Risk Factors

Successful Statin Reintroduction

Management of Statin-Related AEs

Sample Uniform Prior Authorization and Appeals Letters

Improving PCSK9 Inhibitor Approval Rates

Real-World Experience With FH and PCSK9 Inhibitors

Navigating the Prior Authorization Process With the Patient

Clinical Management of the Patient With Dyslipidemia

Specialty Pharmacy PCSK9 Inhibitor Access

Clinical Tips for Therapeutic Management of PCSK9 Inhibitors

Conclusion

Abbreviations

Abbreviations (cont)